Details

Autor(en) / Beteiligte

• Isonishi, Seiji
• Kikuchi, Yoshihiro

Titel

Molecular Diagnosis and Targeting for Gynecologic Malignancy

Auflage

1

Ort / Verlag

Singapore: Springer Singapore Pte. Limited

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• This book summarizes the important developments in the field of cancer research, specifically uterine cervical/endometrial cancer and ovarian cancer. It highlights the recent advances in gynecologic cancer, such as next generation models of genetically engineered animal models or cancer cell lines, focusing on their significance for advancing our understanding of gynecologic cancer biology, prevention and treatment, and drug response and resistance.Cancer research in the area of gynecologic tumors has undergone an enormous transformation over the past decade, with a greater understanding of tumor biology, elucidation of novel targets for therapeutic intervention, and better recognition of genetic predisposition syndromes. At the same time, the recent advances in basic cancer research have provided key insights into all aspects of gynecologic cancer biology, including developmental pathways and the impact of lineage plasticity, understanding metastatic progression, uncovering the roles of the tumor microenvironment , exploring tumor evolution, and discovering new therapeutic approaches and mechanisms of drug sensitivity and adaptive response. Molecular Diagnosis and Targeting for Gynecologic Malignancy appeals to investigators, clinicians, residents and postdocs who are curious about new research on gynecologic malignancies. It not only presents basic and translational research, but also explores the generalizability of the evidence covering the interface between basic and clinical science. Furthermore, a number of the topics offer the basis for new ideas that have the potential to advance into the gynecologic malignancies. This book provides readers with state-of-the-art information that will help improve the lives of patients with these challenging diseases.